Navigation Links
Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
Date:10/19/2007

y to any component of the vaccine or to latex, which is used in the vial stopper. Guillain-Barre syndrome (GBS) has been reported in temporal relationship following administration of Menactra vaccine. Persons previously diagnosed with GBS should not receive Menactra(R) vaccine. As with any vaccine, vaccination with Menactra(R) vaccine may not protect 100 percent of individuals.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The Company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their u
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
5. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
8. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
9. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
10. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... Planning for Phase 3 Trial Initiation on Track ... Limited (ASX: PGL; Nasdaq: PGLA) today announced it ... Contract Research,Organisation, to utilise their services for a ... the execution of the,Phase 3 clinical trial of ...
... Topic of Drug Repurposing and ... Indian Clinical Trial Strategy, ... biopharmaceutical company, announced today,that Chief Executive Officer, John Maki, and ... 234th American Chemical,Society National Meeting on Sunday, August 19, 2007. ...
Other Medicine Technology:Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... meant to treat Parkinsons disease has been associated with ... who were not gamblers otherwise. ,The Mayo Clinic ... on such a link between gambling and the drug ... of the nervous system. Some of its symptoms are ...
... study of treating obesity have identified a gene FOX gene,// ... explains why people despite not eating too much tend to ... obesity is input of food being greater than the energy ... ,The answer thus lies in genetics. The gene studied ...
... various immune deficiency syndromes, and researchers// have been able ... of immune deficiency conditions called immunoglobulin A (IgA) deficiency ... may be hereditary or acquired. Hereditary or primary immune ... cells and tissues that are responsible for our immune ...
... warning regarding the consumption of Liqiang 4 Dietary Supplement Capsules// ... serious, life-threatening consequences in some people. The warning from the ... through an anonymous consumer complaint which was followed up with ... ,Glyburide is a drug used to lower blood ...
... the children of suspected child abuse tend to differ ... A research reported by the researchers of Penn State ... among the doctors themselves regarding their opinion of whether ... the first systematic examination of how the pediatricians report ...
... AIDS Vaccine Initiative (IAVI) together with GlaxoSmithKline Biologicals// ... develop an AIDS vaccine using a new technology. ... from research conducted by scientists at the University ... University and is exclusively licensed to GSK. ...
Other Medicine News:Health News:Developing a new vaccine using a new technology 2
... the revolutionary OxiMax® Pulse Oximetry System, ... Nellcor's best-in-class pulse oximetry with the ... OxiMax N-595 Pulse Oximeter is equipped ... technology, which enables it to withstand ...
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... The Autocorr Pulse Oximeter with SAC ... unique patented software to extract SpO 2 ... in a new way. This cost-effective ... study functions as standard features, and a ...
Medicine Products: